---
figid: PMC2801866__nihms162154f4
figlink: /pmc/articles/PMC2801866/figure/F4/
number: Figure 4
caption: The NO/cGMP pathway is a signaling node for pro- and anti-angiogenic signaling.
  In addition to VEGF, angiopoietin-1, estrogens, and insulin can activate eNOS to
  increase NO synthesis in endothelial cells. TSP1 signaling via CD36 and CD47 inhibits
  downstream elements of this pathway. Oxidized LDL (oxLDL) is another known ligand
  of CD36 that could inhibit angiogenesis via an overlapping pathway. In addition,
  oxLDL signaling inhibits protein kinase Cα, which phosphorylates eNOS at Thr495
  and activates NADPH oxidase (NOX), and the resulting superoxide depletes NO levels.
  The angiogenesis inhibitors endostatin and vasoinhibins activate the phosphatase
  PP2A, which dephosphorylates and thereby inactivates eNOS.
pmcid: PMC2801866
papertitle: Molecular Regulation of Tumor Angiogenesis and Perfusion via Redox Signaling.
reftext: Thomas W. Miller, et al. Chem Rev. ;109(7):3099-3124.
pmc_ranked_result_index: '4953'
pathway_score: 0.9070026
filename: nihms162154f4.jpg
figtitle: NO/cGMP pathway is a signaling node for pro- and anti-angiogenic signaling
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2801866__nihms162154f4.html
  '@type': Dataset
  description: The NO/cGMP pathway is a signaling node for pro- and anti-angiogenic
    signaling. In addition to VEGF, angiopoietin-1, estrogens, and insulin can activate
    eNOS to increase NO synthesis in endothelial cells. TSP1 signaling via CD36 and
    CD47 inhibits downstream elements of this pathway. Oxidized LDL (oxLDL) is another
    known ligand of CD36 that could inhibit angiogenesis via an overlapping pathway.
    In addition, oxLDL signaling inhibits protein kinase Cα, which phosphorylates
    eNOS at Thr495 and activates NADPH oxidase (NOX), and the resulting superoxide
    depletes NO levels. The angiogenesis inhibitors endostatin and vasoinhibins activate
    the phosphatase PP2A, which dephosphorylates and thereby inactivates eNOS.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - KDR
  - AKT3
  - PGF
  - SGCB
  - VEGFA
  - PLCG2
  - AKT1
  - HSP90AA1
  - VEGFC
  - PLCG1
  - MAPK3
  - VEGFD
  - MAPK8
  - SRC
  - VEGFB
  - NOS3
  - MAPK12
  - CD36
  - PRKCA
  - MAPK14
  - MAPK1
  - MAPK10
  - FYN
  - CD47
  - MAPK13
  - MAPK9
  - AKT2
  - MAPK11
  - Endostatin
  - Cancer
genes:
- word: VEGFR2
  symbol: VEGFR2
  source: hgnc_alias_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: SGC
  symbol: SGC
  source: hgnc_alias_symbol
  hgnc_symbol: SGCB
  entrez: '6443'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: PLCY,
  symbol: PLCG
  source: bioentities_symbol
  hgnc_symbol: PLCG2
  entrez: '5336'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: Hsp90
  symbol: Hsp90
  source: hgnc_alias_symbol
  hgnc_symbol: HSP90AA1
  entrez: '3320'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: PLCY,
  symbol: PLCG
  source: bioentities_symbol
  hgnc_symbol: PLCG1
  entrez: '5335'
- word: PLCY,MAPK,Fyn/Src
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: PLCY,MAPK,Fyn/Src
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: PLCY,MAPK,Fyn/Src
  symbol: SRC
  source: hgnc_symbol
  hgnc_symbol: SRC
  entrez: '6714'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: ENOS
  symbol: eNOS
  source: hgnc_alias_symbol
  hgnc_symbol: NOS3
  entrez: '4846'
- word: PLCY,MAPK,Fyn/Src
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: CD36
  symbol: CD36
  source: hgnc_symbol
  hgnc_symbol: CD36
  entrez: '948'
- word: PKCa
  symbol: PKCA
  source: hgnc_prev_symbol
  hgnc_symbol: PRKCA
  entrez: '5578'
- word: PLCY,MAPK,Fyn/Src
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: PLCY,MAPK,Fyn/Src
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PLCY,MAPK,Fyn/Src
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: PLCY,MAPK,Fyn/Src
  symbol: FYN
  source: hgnc_symbol
  hgnc_symbol: FYN
  entrez: '2534'
- word: CD47
  symbol: CD47
  source: hgnc_symbol
  hgnc_symbol: CD47
  entrez: '961'
- word: PLCY,MAPK,Fyn/Src
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: PLCY,MAPK,Fyn/Src
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PLCY,MAPK,Fyn/Src
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
chemicals:
- word: Endostatin
  source: MESH
  identifier: D043169
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
